Treatment of Retinoblastoma with High-Risk Features: Extraocular Extension, Post-Laminar Optic Nerve Invasion, or Massive Choroidal Invasion

This protocol addresses retinoblastoma presenting with one or more high-risk pathological features — including extraocular extension, post-laminar optic nerve invasion, massive choroidal invasion exceeding 3 mm, or massive ICRB Group E disease occupying more than 50% of the globe — where standard globe-salvage approaches are not appropriate and an escalated management strategy is required.

Clinical Scenario

Enucleation is typically indicated for massive Group E tumors, cases where poor tumor visualization precludes safe monitoring (e.g., vitreous hemorrhage), or when extraocular extension or suspected invasion of the optic nerve or choroid is identified. It is also appropriate for tumors that have not responded to prior globe-salvage attempts. The presence of post-laminar optic nerve invasion, massive choroidal invasion (>3 mm), or extraocular extension on histopathology signals an elevated risk of metastatic spread that must be addressed.

Treatment Approach (Partial Overview)

Management is anchored by surgical removal of the affected eye. When high-risk histopathological features are confirmed after enucleation, adjuvant high-dose intravenous chemotherapy is required to reduce the risk of metastatic disease. The complete protocol — including agent selection, sequencing, and the full decision algorithm — is available via the structured regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.4103/ijo.IJO_721_20

High risk retinoblastoma warrants enucleation and additional 6‑9 cycles of high‑dose IVC to prevent metastatic disease.
In the presence of high risk features, including post‑laminar optic nerve invasion, massive choroidal invasion (>3 mm diameter), or extraocular extension, adjuvant IVC is required for prevention of metastases.
It is usually reserved for massive group E tumors, poor tumor visualization (e.g., due to vitreous hemorrhage), presence of extraocular extension, suspected invasion of the optic nerve or choroid, or recalcitrant tumors that have failed previous globe salvage therapies (e.g., IAC, IvitC, plaque radiotherapy, etc.).

View source ↗